Form 4: MiMedx Group CFO Doug Rice Receives Stock and Option Grants

Doug Rice, CFO of MiMedx Group, received a grant of restricted stock and stock options on March 1, 2024.

Summary

• On March 1, 2024, Doug Rice, the Chief Financial Officer of MiMedx Group, Inc., was granted 58,478 shares of restricted stock.
• These shares vest fully on the third anniversary of the grant date, contingent upon continued employment.
• Rice also received options to purchase 70,755 shares of common stock at an exercise price of $8.63.
• These options vest 25% annually from the grant date, also subject to continued employment, and expire on March 1, 2031.
• Following these transactions, Rice beneficially owns 160,678 shares of common stock and options for 164,755 shares.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a standard executive compensation event. The sentiment is slightly positive as it indicates the company is incentivizing its CFO with equity, aligning his interests with shareholders.

Positives

• The grant of restricted stock and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules incentivize continued employment and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the equity grants suggest an expectation of continued employment and contribution from the CFO.

Industry Context

Equity grants are a common practice in the pharmaceutical and biotechnology industries to incentivize key executives and align their interests with those of shareholders. The size and vesting schedule of the grant are typical for a CFO role in a company of MiMedx's size.

Comparison to Industry Standards

• Stock option and restricted stock grants are standard compensation practices for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Organogenesis and Integra LifeSciences also utilize similar equity-based compensation packages for their executive teams.
• The vesting schedules (3 years for restricted stock, annual vesting for options) are also typical within the industry, designed to retain key personnel and align their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with long-term value creation.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates